Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Seton Healthcare Family
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 1 Week
Study Overview
Brief Summary
Symptomatic treatment of the negative symptoms in schizophrenia (such as social withdrawal, affective flattening, poor motivation, and apathy) with medications and psychotherapy are almost non-existent, whereas treatment of the positive symptoms (hallucinations and delusions) has been more effective with psychotropic medications. The proposed research on human subjects using a non-invasive technology (such as repetitive transcranial magnetic stimulation [rTMS]) will provide efficacy data for treating negative symptoms.
The hypotheses are that 1) Cerebellar stimulation will cause activation of thalamic and frontal cortical networks associated with attentional processes as a component of the "distracted" affect of schizophrenia; 2) Cerebellar stimulation will cause activation of the reticular activating system (RAS), and this will allow the "mutism", which is a negative symptom, to be partially improved.
Detailed Description
Background and Significance
There is increasing evidence from neuropsychological and imaging studies that cerebellar function is relevant not only to motor coordination, but equally to cognition and behavior (Rapoport et al., 2000). Selective modulation of cerebello-thalamocortical pathways, in turn, is believed to provide an additional means of modulating cortical function. Repetitive transcranial magnetic stimulation (rTMS) can modulate cortical excitability focally in conscious subjects. Trains with slow frequency (i.e.,1 Hz) are known to suppress cortical excitability (Chen et al., 1997), whereas facilitation occurs if frequencies higher than 5 Hz are used (Berardelli et al., 1998). With respect to rTMS of the cerebellum, a major impact on cognitive function (Oliveri et al., 2007) has been described.
The cerebellum is a very good candidate to be the generator for intracortical inhibition; its stimulation can modulate the cortical inhibition. Invasive studies by Robert Heath at Tulane University revealed that the cerebellum is strongly connected to 2 structures at the core of the proposed abnormal circuitry in schizophrenia, the septal nuclei and the hippocampus (HC). According to his theory and findings, the septal nuclei are involved in positive mood regulation, pleasure. The firing of the HC was correlated with negative affect and sadness (Heath et al, 1980). By stimulating the fastigial nucleus and vermis of the cerebellum, the septal nuclei were facilitated to fire and the HC was inhibited. The other component of what Heath referred to as the "aversive system", the amygdala was also inhibited. This central role of the cerebellum in this circuit is analogous to its role in "smoothing" the flow of movements. When considering emotion and cognition, the cerebellum has a smoothing function. Aside from direct monosynaptic connections between these sites, there is evidence that the deep cerebellar nuclei are connected to the parietal cortex, temporal cortex, as well as the cingulate gyrus. These are all areas that have limbic function. The cerebellum is also directly connected to the midbrain reticular activating system (RAS). This region is responsible for levels of consciousness and arousal. By potentiating the activation of the RAS, wthe investigators e can increase the decreased level of arousal, which in many schizophrenia patients is akin to psychomotor retardation and mutism (catatonic). Midline deep cerebellar nuclei efferents have been traced to the hypothalamus, central nuclei of the thalamus, which are also associative (cognitive) and limbic in function. The Locus Ceruleus and the substantia nigra, in the brain stem are also monosynaptically connected to the cerebellum.
The cerebellum is connected to thalamus and motor cortex (frontal cortex) through cerebello-thalamo-cortical pathway. And as stated above it is also connected to a vast array of limbic structures, making it a good choice to use to modulate abnormal activity in these structures.
Purkinje cells, the output neurons of cerebellar cortex reduce the excitatory drive from the deep cerebellar nuclei via the ventrolateral thalamus to inhibitory neurons in the motor cortex. Activation of Purkinje cells will inhibit the thalamic drive to intracortical inhibitory neurons, therefore, decrease the intracortical inhibitory interneuron activity and decrease in SICI and CSP. On the other hand, inhibition of Purkinje cerebellar cells is expected to have opposite effect and release the thalamus from inhibitory control, increase the thalamic drive to stimulate the inhibitory interneurons which can be demonstrated by increase in SICI and CSP Indeed, applying inhibitory rTMS at frequency of 1 Hz resulted in increase in SICI (Langguth et al., 2008).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients enrolling to the study:
- •must be stable on their medications at the start of their enrollment in the study and throughout the duration of the study;
- •must have no history of substance use of substance-dependence issues over at least the past six months;
- •must be able to and have the capacity to provide consent;
- •and if older patient, he/she must be able to participate without a safeguard to be present.
Exclusion Criteria
- •Patients excluded from the study are:
- •Patients with typical clinical considerations that exclude them from treatment with TMS (i.e., patients who have had head injuries, patients with metal implants, patients with a history of seizures, patients with elevated risk of seizures, patients who are taking medications that may interfere with TMS or potentiate the related side effects, etc.).
- •Patients who have had changes in their medications (i.e., patients must be stable on their medications throughout their participation in the study).
- •Patients with history of substance abuse or substance-dependence anytime over the past six months.
- •Patients who are unable (i.e., do not have the capacity) to consent.
Arms & Interventions
Active
Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
Intervention: 1 Hz rTMS (Device)
Active
Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
Intervention: 10 Hz rTMS (Device)
Placebo
Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
Intervention: 1 Hz rTMS (Device)
Placebo
Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
Intervention: 10 Hz rTMS (Device)
Outcomes
Primary Outcomes
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 1 Week
Time Frame: Participants will be followed for an expected average of 5 weeks
Participants will receive baseline and post-treatment protocol neuropsychiatric measures. These rating scales are accepted and standardized.
Secondary Outcomes
- Change From Baseline in Electroencephalographic (EEG) Measures at 1 Week(Participants will be followed for an expected average of 5 weeks)
Investigators
Robert J. Buchanan
Chief of Functional and Restorative Neurosurgery and Neurosciences
Seton Healthcare Family
